ECO Animal Health shares surge on poultry drug milestone.

The share price of ECO Animal Health surged on Monday after European regulators recommended marketing authorisation for its poultry vaccine ECOVAXXIN MS.

ECO Animal Health Group
10 November 2025 12:09:03

Source: Sharecast

The AIM-listed company, which focuses on treatments for respiratory and enteric diseases in pigs and poultry, said the key milestone now establishes a roadmap for the commercial launch of the drug in the second half of 2026.

ECOVAXXIN MS is an immunisation against mycoplasma synoviae, which can cause air-sac and foot-pad lesions in poultry, which can result in a 5-10% reduction in the number of eggs laid by affected hens.

David Hallas, chief executive of ECO Animal Health, said he was "delighted" by the announcement from the the Committee for Medicinal Products for Veterinary Use of the European Medicines Agency.

"This marks an exciting time for the company, with further submissions expected over the next 12 months for additional products from our R&D pipeline, underpinning ECO's next phase of growth."

The stock was up 8.4% at 87.8p by 1136 GMT.

N/A

ISIN: N/A

Exchange: N/A

Sell:

N/A

Buy:

N/A

Change:

Date:

Prices delayed by at least 15 minutes

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.